☐  issuer tender offer subject to Rule 13e-4. ☐  going-private transaction subject to Rule 13e-3. ☐  amendment to Schedule 13D under Rule 13d-2. Except as otherwise set forth in this Amendment No. 1, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment No. 1.

✦ULYX is conducting a tender offer, likely enabling shareholders to sell shares back to the company or an acquirer at a specified price, which could signal a potential going-private transaction or significant ownership change affecting stock liquidity and valuation.

esignate the appropriate rule provision(s) relied upon:   ¨ Rule 13e-4(i) (Cross-Border Issuer Tender Offer).   ¨ Rule 14d-1(d) (Cross-Border Third Party Tender Offer).         This Amendment No. 2 to the Tender Offer Statement on Schedule TO (this “Amendment No. 2”) amends and supplements the Tender Offer Statement on Schedule TO filed by Ravens Sub, Inc., a Delaware corporation (“Purchaser”), and wholly owned subsidiary of Gilead Sciences, Inc., a Delaware corporation (“Parent”

✦Gilead Sciences is proceeding with its tender offer to acquire Arcalyx (ACLX), signaling commitment to the deal despite market conditions and potentially offering shareholders a defined exit opportunity at the offered price.

ssuer tender offer subject to Rule 13e-4. ☒ going-private transaction subject to Rule 13e-3.   ☐ amendment to Schedule 13D under Rule 13d-2. This Schedule TO relates to the offer by the Buyer Parties to purchase all of the issued and outstanding shares (each, a “ Share ” and collectively, the “ Shares ”) of common stock, par value $0.001 per share, of Forian Inc., a Maryland corporation (the “ Company ”), for $2.17 per Share, payable net to the holder in cash, without interest, subject to any withholding taxes required by a

✦FORA shareholders can sell shares at $2.17/share in a going-private transaction, representing the acquisition price investors should compare against current trading value to assess deal attractiveness.

Offer price: $5.05 per share. Expires: May 11, 2026.

Offer price: $5.05 per share. Expires: May 11, 2026.